作者: Nicholas R. Bachur
DOI: 10.1007/978-1-4613-4349-3_10
关键词: Cancer research 、 Soft tissue sarcoma 、 Myelogenous 、 Breast cancer 、 Acute lymphocytic leukemia 、 Vomiting 、 Daunorubicin 、 Acute leukemia 、 Medicine 、 Lung cancer
摘要: Over the past eight years, adriamycin, outstanding representative of anthracycline antibiotics, has demonstrated a remarkable activity against human and animal malignancies (1,2). Whereas adriamycin’s sibling, daunorubicin, been impressive for remission induction in acute myelogenous lymphocytic leukemias, adriamycin wider spectrum is useful solid tumors. Clinical investigators Europe, Americas, Asia, Africa find anticancer soft tissue sarcomas, breast cancer, lung hepatomas, lymphomas, etc. Against some malignancies, no pharmacologic activity. Complicating usage both daunorubicin are toxic effects: myelosuppression, stomatitis, nausea, vomiting, alopecia, electrocardiographic changes, serious cumulative dosage related myocardiopathy.